Top 4 Health Care Stocks That Could Blast Off This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Eagle Pharmaceuticals, Inc. EGRX

Eagle Pharmaceuticals announced it will be delaying the release of third-quarter results to review potential adjustments relating to the reporting of sales of PEMFEXY prior to filling its Form 10-Q. The company’s stock has a 52-week low of $8.32 .
RSI Value: 21.46
EGRX Price Action: Shares of Eagle Pharmaceuticals fell 2.2% to close at $8.64 on Thursday.

Acutus Medical, Inc. AFIB

Acutus Medical reported third-quarter financial results and announced strategic realignment of resources and corporate restructuring by approximately 65%. It has a 52-week low of $0.16.
RSI Value: 24.39
AFIB Price Action: Shares of Acutus Medical fell 11% to close at $0.1851 on Thursday.

Becton, Dickinson and Company BDX

Becton, Dickinson reported mixed fourth-quarter financial results and issued FY24 adjusted EPS and revenue guidance below estimates. "We achieved another quarter, and another year, of strong performance through our talented team's execution of our BD2025 strategy and differentiated portfolio of medical technologies that are increasing healthcare efficiency and improving the lives of patients around the world," said Tom Polen, chairman, CEO and president of BD. The company’s stock has a 52-week low of $219.79.
RSI Value: 29.23
BDX Price Action: Shares of Becton, Dickinson gained 0.6% to close at $235.07 on Thursday.

Ventyx Biosciences, Inc. VTYX

Ventyx Biosciences posted in-line loss for the third quarter. Raju Mohan, Chief Executive Officer said, “We look forward to providing important pipeline updates in the first quarter of 2024, including the VTX958 Phase 2 Crohn’s disease interim efficacy analysis, an update from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis, Phase 2 data for our peripheral NLRP3 inhibitor, VTX2735, in CAPS, and Phase 1 data for our novel CNS penetrant NLRP3 inhibitor, VTX3232, in healthy volunteers.” The company’s 52-week low is $2.2750.
RSI Value: 10.50
VTYX Price Action: Shares of Ventyx Biosciences closed at $2.36 on Thursday.